截至月份: 2025年11月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 德視佳國際眼科有限公司 呈交日期: 2025年12月1日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01846 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 1,000,000,000 | USD | | 0.01 | USD | | 10,000,000 | | 增加 / 減少 (-) | | | | | | | USD | | | | 本月底結存 | | | 1,000,000,000 | USD | | 0.01 | USD | | 10,000,000 | 本月底法定/註冊股本總額： USD 10,000,000 股份發行人及根據《上市規則》第十九B ...

Core Viewpoint - The company, 德视佳 (01846.HK), reported an increase in the total number of ophthalmic surgeries performed in Q3 2025, reaching 6,807 cases, which is approximately 5.6% higher than the same period in 2024 [1] Summary by Category Company Performance - The total number of ophthalmic surgeries in Q3 2025 was 6,807, up from 6,445 in Q3 2024 [1] - The growth in surgeries is attributed to an increase in the number of lens replacement surgeries and a recovery in laser surgery volumes [1] Market Demand - The positive change in surgery numbers reflects a growing patient demand, contributing to the overall performance improvement of the company [1]

德视佳(01846)发布公告，于2025年第三季度，本集团进行的眼科手术总数为6807例，较2024年同期增 加约5.6%(于2024年9月30日：6445例)。有关增长主要是由于晶体置换手术数量增加以及激光手术量恢 复。该积极变化反映于2025年第三季度的患者需求不断增长，有助于提升整体表现。 ...

Core Viewpoint - The company reported a total of 6,807 ophthalmic surgeries in Q3 2025, representing an increase of approximately 5.6% compared to the same period in 2024, driven by a rise in lens replacement surgeries and a recovery in laser procedures [1] Summary by Category Company Performance - The total number of ophthalmic surgeries performed by the company in Q3 2025 was 6,807, up from 6,445 in Q3 2024 [1] - The growth in surgeries is attributed to an increase in lens replacement surgeries and a recovery in laser surgery volumes [1] Market Demand - The positive change in surgery numbers reflects a growing patient demand, contributing to the overall performance of the company [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部份內容而產生或因倚賴 該等內容而引致之任何損失承擔任何責任。 EuroEyes International Eye Clinic Limited 德視佳國際眼科有限公司 （於開曼群島註冊成立的有限公司） （股份代號：1846） 自願公告 2025年第三季度的眼科手術總數 德視佳國際眼科有限公司（「本公司」，連同其附屬公司，統稱「本集團」）自願刊發 本公告。本公司董事（「董事」）會（「董事會」）謹此宣佈，根據本公司的初步統計 數據及本公司目前可得的資料，統計本集團於2025年7月1日至2025年9月30日期 間（「2025年第三季度」）進行的眼科手術（統稱「眼科手術」）總數。 於2025年第三季度，本集團進行的眼科手術總數為6,807例，較2024年同期增加 約5.6%（於2024年9月30日：6,445例）。有關增長主要是由於晶體置換手術數量 增加以及激光手術量恢復。該積極變化反映於2025年第三季度的患者需求不斷增 長，有助於提升整體表現。 本公告所載數字未經審核 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年10月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 德視佳國際眼科有限公司 呈交日期: 2025年11月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01846 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 1,000,000,000 | USD | | 0.01 | USD | | 10,000,000 | | 增加 / 減少 (-) | | | | | | | USD | | | | 本月底結存 | | | 1,000,000,000 | USD | | 0.01 | USD | | 10,000,000 | 本月底法定/註 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年9月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 德視佳國際眼科有限公司 呈交日期: 2025年10月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01846 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 1,000,000,000 | USD | | 0.01 | USD | | 10,000,000 | | 增加 / 減少 (-) | | | | | | | USD | | | | 本月底結存 | | | 1,000,000,000 | USD | | 0.01 | USD | | 10,000,000 | 本月底法定/註冊 ...

NOTIFICATION LETTER 通知信函 Dear Non-registered Holder(s)(Note 1) , EuroEyes International Eye Clinic Limited (the "Company") - Notification of publication of 2025 Interim Report (the "Current Corporate Communications") The English and Chinese versions of the Company's Current Corporate Communications are available on the Company's website at ir.euroeyes.hk and the website of The Stock Exchange of Hong Kong Limited (the "Stock Exchange") at www.hkexnews.hk respectively (the "Website Version"). The Company stro ...

NOTIFICATION LETTER 通知信函 Dear Registered Shareholders. EuroEyes International Eye Clinic Limited (the "Company") – Notice of publication of 2025 Interim Report ("Current Corporate Communications") The English and Chinese versions of the Company's Current Corporate Communications are now available on the Company's website at ir.euroeyes.hk and the website of The Stock Exchange of Hong Kong Limited (the "Stock Exchange") at www.hkexnews.hk respectively (the "Website Version"). The Company strongly recommends ...

Financial Performance - Revenue for the six months ended June 30, 2025, was HKD 377,125,000, representing a 2.4% increase from HKD 368,372,000 in 2024[8] - Gross profit for the same period was HKD 156,816,000, up 5.9% from HKD 148,013,000 in 2024[8] - Adjusted net profit after tax decreased by 37.7% to HKD 38,817,000 from HKD 62,285,000 in 2024[8] - The company reported a net profit of HKD 40,405,000, down 12.7% from HKD 46,309,000 in the previous year[8] - Adjusted gross profit was HKD 156,816,000, slightly down by 0.8% from HKD 158,146,000 in 2024[8] - Operating profit increased to HKD 72,554,000, representing an increase of 10.0% from HKD 65,741,000 in 2024[23] - Profit before tax decreased to HKD 57,797,000, down 18.0% from HKD 70,444,000 in the previous year[23] - Total comprehensive income for the period was HKD 202,230,000, significantly higher than HKD 32,341,000 in the same period last year[24] - Basic earnings per share for the period was HKD 11.999, a decrease from HKD 13.311 in 2024[24] - EBITDA for the same period is HKD 131,821,000, leading to a profit before tax of HKD 57,797,000[59] Assets and Liabilities - Total assets as of June 30, 2025, amounted to HKD 1,811,810, an increase of 13.2% from HKD 1,599,435 as of December 31, 2024[17] - Non-current assets increased to HKD 996,664, up 12.5% from HKD 885,835 at the end of 2024[17] - Total liabilities as of June 30, 2025, were HKD 512,513, an increase of 8.2% from HKD 473,721 at the end of 2024[21] - The company’s equity attributable to owners increased to HKD 1,264,762, up 15.7% from HKD 1,092,965 at the end of 2024[17] - Cash and cash equivalents reached HKD 741,782, representing a 13.5% increase from HKD 653,232 at the end of 2024[17] - Trade receivables increased significantly to HKD 14,171, up from HKD 4,738 at the end of 2024, indicating a growth of 198.5%[17] Foreign Exchange and Financial Management - The financial results reflect the impact of pre-opening expenses for new clinics and foreign exchange losses related to global offerings[9] - The company reported a foreign exchange loss related to global offering proceeds of HKD 513, compared to HKD 323 in 2024[11] - The company experienced a foreign exchange loss due to the appreciation of the Euro against the RMB and HKD by 11.7% and 13.4%, respectively[112] - The group maintains a prudent liquidity risk management policy, ensuring sufficient cash and credit facilities[42] - The expected credit loss rate for cash and cash equivalents is assessed as not significant, with no provisions made as of June 30, 2025[41] Strategic Outlook and Growth Plans - The management plans to continue focusing on market expansion and new clinic openings to drive future growth[10] - The company is committed to enhancing its service offerings through the development of new technologies and products[10] - Future guidance indicates a cautious outlook due to the current economic environment and its impact on consumer spending[10] - The company anticipates a compound annual growth rate (CAGR) of 10% for revenue and 20% for net profit by 2028, supported by a diversified global business portfolio[120] - The company plans to actively seek suitable acquisition opportunities to significantly enhance organic growth over the next two to three years[120] Employee and Operational Expenses - Employee benefits expenses decreased slightly to HKD 122,204,000 in 2025 from HKD 123,470,000 in 2024, a reduction of 1.0%[72] - Selling expenses increased by 14.9% to HKD 41.8 million, representing 11.1% of total revenue, up from 9.9% in 2024[132] - Administrative expenses were HKD 48.8 million, consistent with the previous year, accounting for 12.9% of total revenue, down from 13.2%[134] Shareholder Information - The company proposed an interim dividend of HKD 0.0315 per share for the six months ended June 30, 2025, totaling HKD 10,102,239, compared to HKD 11,570,153 in 2024[83] - The company has not issued any further share-based payments since 2025, indicating a potential shift in compensation strategy[94] - The total issued shares as of June 30, 2025, were 320,706,000[156] - Dr. Jørn Slot Jørgensen holds a controlling interest of 57.65% in the company[152] Governance and Compliance - The company has maintained compliance with the corporate governance code as per the listing rules, with a review of governance procedures conducted[168] - The board believes that the current governance structure does not undermine the balance of power and authority within the company[169] - The audit committee reviewed the unaudited condensed consolidated results for the six months ended June 30, 2025, and had no objections to the accounting treatments adopted[178]